Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma

Cereblon (CRBN) is essential for the anti-myeloma (MM) activity of immunomodulatory drugs (IMiDs), such as thalidomide and lenalidomide. However, the clinical implications of CRBN in MM patients are unclear. Using immunohistochemical (IHC) staining on paraffin-embedded bone marrow sections, the expr...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Huang, Shang-Yi, Lin, Chung-Wu, Lin, Hsiu-Hsia, Yao, Ming, Tang, Jih-Luh, Wu, Shang-Ju, Chen, Yao-Chang, Lu, Hsiao-Yun, Hou, Hsin-An, Chen, Chien-Yuan, Chou, Wen-Chien, Tsay, Woei, Chou, Sheng-Je, Tien, Hwei-Fang
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Springer Berlin Heidelberg 2014
Θέματα:
Original Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4082140/
https://ncbi.nlm.nih.gov/pubmed/24687382
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-014-2063-7
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια